D. Rocco, L. Della Gravara, P. Maione, G. Palazzolo, C. Gridelli
{"title":"肿瘤对靶向治疗无反应的肺癌患者联合用药的鉴定:临床基础和未来方向","authors":"D. Rocco, L. Della Gravara, P. Maione, G. Palazzolo, C. Gridelli","doi":"10.1080/23808993.2022.2050369","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction Targeted therapies have granted unprecedented results in terms of survival and safety to oncogene-addicted advanced NSCLC patients. However, these patients eventually become unresponsive to such treatments due to several different resistance mechanisms. Moreover, the current lack of subsequent-line treatments forces these patients to receive less tolerable and less effective chemotherapy regimens. Areas covered Thus, this paper aims to review the current state of the art with respect to targeted therapies for the treatment of oncogene-addicted advanced NSCLC patients, focusing on resistance mechanisms and on drug combinations to overcome them. Expert opinion We strongly believe that a personalized sequential treatment approach based on resistance mutations will become the standard of care for oncogene-addicted advance NSCLC patients. Furthermore, we believe that TKI combination regimens will play a key role. In the same vein, ICI-containing regimens will play a part both in patients without druggable resistance mutations and in patients progressing on TKI therapies.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"7 1","pages":"29 - 38"},"PeriodicalIF":1.0000,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions\",\"authors\":\"D. Rocco, L. Della Gravara, P. Maione, G. Palazzolo, C. Gridelli\",\"doi\":\"10.1080/23808993.2022.2050369\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction Targeted therapies have granted unprecedented results in terms of survival and safety to oncogene-addicted advanced NSCLC patients. However, these patients eventually become unresponsive to such treatments due to several different resistance mechanisms. Moreover, the current lack of subsequent-line treatments forces these patients to receive less tolerable and less effective chemotherapy regimens. Areas covered Thus, this paper aims to review the current state of the art with respect to targeted therapies for the treatment of oncogene-addicted advanced NSCLC patients, focusing on resistance mechanisms and on drug combinations to overcome them. Expert opinion We strongly believe that a personalized sequential treatment approach based on resistance mutations will become the standard of care for oncogene-addicted advance NSCLC patients. Furthermore, we believe that TKI combination regimens will play a key role. In the same vein, ICI-containing regimens will play a part both in patients without druggable resistance mutations and in patients progressing on TKI therapies.\",\"PeriodicalId\":12124,\"journal\":{\"name\":\"Expert Review of Precision Medicine and Drug Development\",\"volume\":\"7 1\",\"pages\":\"29 - 38\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Precision Medicine and Drug Development\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23808993.2022.2050369\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2022.2050369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions
ABSTRACT Introduction Targeted therapies have granted unprecedented results in terms of survival and safety to oncogene-addicted advanced NSCLC patients. However, these patients eventually become unresponsive to such treatments due to several different resistance mechanisms. Moreover, the current lack of subsequent-line treatments forces these patients to receive less tolerable and less effective chemotherapy regimens. Areas covered Thus, this paper aims to review the current state of the art with respect to targeted therapies for the treatment of oncogene-addicted advanced NSCLC patients, focusing on resistance mechanisms and on drug combinations to overcome them. Expert opinion We strongly believe that a personalized sequential treatment approach based on resistance mutations will become the standard of care for oncogene-addicted advance NSCLC patients. Furthermore, we believe that TKI combination regimens will play a key role. In the same vein, ICI-containing regimens will play a part both in patients without druggable resistance mutations and in patients progressing on TKI therapies.
期刊介绍:
Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.